Clinical Trial Update: CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CIMAvax-EGF in combination with a KRAS G12C inhibitor for advanced KRAS G12C-mutated non-small cell lung cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CIMAvax-EGF (EGF-depleting vaccine CIMAvax-EGF)
• KRAS G12C inhibitor

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Status: NOT_YET_RECRUITING